Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical and Demographic Characteristics and Two-Year Efficacy and Safety Data of 508 Multiple Sclerosis Patients with Fingolimod Treatment.
Terzi M, Helvacı EM, Şen S, Boz C, Çilingir V, Akçalı A, Beckmann Y, Uzunköprü C, Türkoğlu R, Yüceyar N, Efendi H, Bünül SD, Seferoğlu M, Kotan D, Güler S, Balcı BP, Öztürk B, Mungan S, İçen NK, Ömerhoca S, Yurtoğulları Ş, Sevim S, Türkoğlu ŞA, Çam M, Yetkin MF, Yoldaş TK, Sıvacı AÖ, Gökçe ŞF, Gürsoy E, Ünal A, Bilge N, Ağan K, Toprak MK, Koçer B, Sezer G, Terzi Y. Terzi M, et al. Among authors: yuceyar n. Noro Psikiyatr Ars. 2023 Jan 13;60(1):23-27. doi: 10.29399/npa.28081. eCollection 2023. Noro Psikiyatr Ars. 2023. PMID: 36911568 Free PMC article.
Overactive bladder symptoms in patients with multiple sclerosis: Frequency, severity, diagnosis and treatment.
Akkoç Y, Ersöz M, Yüceyar N, Tunç H, Köklü K, Yoldaş TK, Dönmez Ü, Uzunköprü C, Alemdaroğlu E, Bilen Ş, Emre U, Özdolap Ş, Tuncay E, Yücesan C, Gök H, Ercan MB, Uygunol K, Koçer B, Zinnuroğlu M; Neurogenic Bladder Turkish Research Group. Akkoç Y, et al. Among authors: yuceyar n. J Spinal Cord Med. 2016;39(2):229-33. doi: 10.1179/2045772315Y.0000000021. Epub 2016 Feb 15. J Spinal Cord Med. 2016. PMID: 25936385 Free PMC article.
Comparative analysis of fingolimod versus teriflunomide in relapsing-remitting multiple sclerosis.
Boz C, Terzi M, Özer B, Turkoglu R, Karabudak R, Efendi H, Soysal A, Sevim S, Altintas A, Kurne A, Akçalı A, Akman G, Yüceyar N, Balcı BP, Ekmekci Ö, Karahan SZ, Demirkıran M, Altunrende B, Turan ÖF, Gökçen GözübatıkÇelik, Kale N, Köseoğlu M, Ozakbas S. Boz C, et al. Among authors: yuceyar n. Mult Scler Relat Disord. 2019 Nov;36:101376. doi: 10.1016/j.msard.2019.101376. Epub 2019 Aug 26. Mult Scler Relat Disord. 2019. PMID: 31473488
A 12-month, Open Label, Multicenter Pilot Study Evaluating Fingolimod Treatment in terms of Patient Satisfaction in Relapsing Remitting Multiple Sclerosis Patients - FINE Trial.
Demır GA, Türkoğlu R, Saıp S, Yüceyar N, Efendı H, Turan ÖF, Ağan K, Terzı M, Boz C, Tuncer A, Koçer B, Kasap M, Çalişkan Z; Fine Study Group. Demır GA, et al. Among authors: yuceyar n. Noro Psikiyatr Ars. 2017 Jun 22;56(4):253-257. doi: 10.5152/npa.2017.20515. eCollection 2019 Dec. Noro Psikiyatr Ars. 2017. PMID: 31903032 Free PMC article.
54 results